- Home
- FSK vs AXSM Comparison
FSK vs AXSM Comparison
Compare FSK & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSK
- AXSM
- Stock Information
- Founded
- FSK 2007
- AXSM 2012
- Country
- FSK United States
- AXSM United States
- Employees
- FSK N/A
- AXSM N/A
- Industry
- FSK Investment Managers
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- FSK Finance
- AXSM Health Care
- Exchange
- FSK Nasdaq
- AXSM Nasdaq
- Market Cap
- FSK 5.4B
- AXSM 5.1B
- IPO Year
- FSK N/A
- AXSM 2015
- Fundamental
- Price
- FSK $19.91
- AXSM $107.76
- Analyst Decision
- FSK Hold
- AXSM Strong Buy
- Analyst Count
- FSK 7
- AXSM 15
- Target Price
- FSK $20.21
- AXSM $170.20
- AVG Volume (30 Days)
- FSK 1.4M
- AXSM 655.3K
- Earning Date
- FSK 05-07-2025
- AXSM 05-05-2025
- Dividend Yield
- FSK 12.86%
- AXSM N/A
- EPS Growth
- FSK N/A
- AXSM N/A
- EPS
- FSK 1.90
- AXSM N/A
- Revenue
- FSK $1,687,000,000.00
- AXSM $432,157,000.00
- Revenue This Year
- FSK N/A
- AXSM $63.52
- Revenue Next Year
- FSK $0.31
- AXSM $63.32
- P/E Ratio
- FSK $10.49
- AXSM N/A
- Revenue Growth
- FSK N/A
- AXSM 72.16
- 52 Week Low
- FSK $17.42
- AXSM $64.11
- 52 Week High
- FSK $24.10
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- FSK 49.71
- AXSM 46.37
- Support Level
- FSK $19.33
- AXSM $103.15
- Resistance Level
- FSK $20.13
- AXSM $120.00
- Average True Range (ATR)
- FSK 0.38
- AXSM 3.51
- MACD
- FSK 0.10
- AXSM 0.66
- Stochastic Oscillator
- FSK 59.25
- AXSM 29.45
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.